Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-1 Inhibitors Maintenance in R/R Classical Hodgkin Lymphoma After Auto-HCT
NCT06812858Phase 2Recruiting
- Sponsor
- First Saint Petersburg State Medical University
- Start
- Jan 2024
- Primary completion
- May 2029
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of nivolumab and pembrolizumab in classical Hodgkin lymphoma (cHL), sponsored by First Saint Petersburg State Medical University. Primary endpoint: Progression-Free Survival at 24 months. Started Jan 2024; status: recruiting.
02
Drugs
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NCT06812858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06812858.